• Citer

The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.

par Dideberg, Vinciane;Théâtre, E;Farnir, F.;Vermeire, Séverine;Rutgeerts, Paul;De Vos, M;Belaiche, Jacques;Franchimont, Denis ;Van Gossum, André ;Louis, Edouard;Bours, Vincent
Référence Pharmacogenetics and genomics, 16, 10, page (727-734)
Publication Publié, 2006-10

Article révisé par les pairs

• Détails
• Contenu

Titre:	The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.
Auteur:	Dideberg, Vinciane; Théâtre, E; Farnir, F.; Vermeire, Séverine; Rutgeerts, Paul; De Vos, M; Belaiche, Jacques; Franchimont, Denis; Van Gossum, André; Louis, Edouard; Bours, Vincent
Informations sur la publication:	Pharmacogenetics and genomics, 16, 10, page (727-734)
Statut de publication:	Publié, 2006-10
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	ADAM 17
	Crohn's disease
	Haplotype
	Infliximab
	Tumour necrosis-α
MeSH keywords:	ADAM Proteins -- genetics
	Adult
	Antibodies, Monoclonal -- therapeutic use
	Base Sequence
	Crohn Disease -- drug therapy
	Crohn Disease -- genetics
	DNA Primers
	Gastrointestinal Agents -- therapeutic use
	Haplotypes
	Humans
	Middle Aged
	Tumor Necrosis Factor-alpha -- genetics
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:1744-6880
	info:doi/10.1097/01.fpc.0000230117.26581.a4
	info:pii/01213011-200610000-00005
	info:scp/33749010045
	info:pmid/17001292